Literature DB >> 32712270

Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Mark D Mannie1, Kayla B DeOca2, Alexander G Bastian2, Cody D Moorman2.   

Abstract

FOXP3+ regulatory T cells (Tregs) constitute a critical barrier that enforces tolerance to both the self-peptidome and the extended-self peptidome to ensure tissue-specific resistance to autoimmune, allergic, and other inflammatory disorders. Here, we review intuitive models regarding how T cell antigen receptor (TCR) specificity and antigen recognition efficiency shape the Treg and conventional T cell (Tcon) repertoires to adaptively regulate T cell maintenance, tissue-residency, phenotypic stability, and immune function in peripheral tissues. Three zones of TCR recognition efficiency are considered, including Tcon recognition of specific low-efficiency self MHC-ligands, Treg recognition of intermediate-efficiency agonistic self MHC-ligands, and Tcon recognition of cross-reactive high-efficiency agonistic foreign MHC-ligands. These respective zones of TCR recognition efficiency are key to understanding how tissue-resident immune networks integrate the antigenic complexity of local environments to provide adaptive decisions setting the balance of suppressive and immunogenic responses. Importantly, deficiencies in the Treg repertoire appear to be an important cause of chronic inflammatory disease. Deficiencies may include global deficiencies in Treg numbers or function, subtle 'holes in the Treg repertoire' in tissue-resident Treg populations, or simply Treg insufficiencies that are unable to counter an overwhelming molecular mimicry stimulus. Tolerogenic vaccination and Treg-based immunotherapy are two therapeutic modalities meant to restore dominance of Treg networks to reverse chronic inflammatory disease. Studies of these therapeutic modalities in a preclinical setting have provided insight into the Treg niche, including the concept that intermediate-efficiency TCR signaling, high IFN-β concentrations, and low IL-2 concentrations favor Treg responses and active dominant mechanisms of immune tolerance. Overall, the purpose here is to assimilate new and established concepts regarding how cognate TCR specificity of the Treg repertoire and the contingent cytokine networks provide a foundation for understanding Treg suppressive strategy.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clonotypic specificity; FOXP3(+) Tregs; Immunological tolerance; T cell antigen receptor; Tolerogenic vaccination

Year:  2020        PMID: 32712270      PMCID: PMC7444458          DOI: 10.1016/j.cellimm.2020.104173

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  228 in total

Review 1.  Thymic and peripheral differentiation of regulatory T cells.

Authors:  Hyang-Mi Lee; Jhoanne Lynne Bautista; Chyi-Song Hsieh
Journal:  Adv Immunol       Date:  2011       Impact factor: 3.543

2.  The post-activation refractory phase: a mechanism to measure antigenic complexity and ensure self-tolerance among mature peripheral T lymphocytes.

Authors:  M D Mannie
Journal:  Med Hypotheses       Date:  1996-12       Impact factor: 1.538

3.  Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.

Authors:  Chie Hotta-Iwamura; Charles Benck; William D Coley; Yi Liu; Yongge Zhao; Juan A Quiel; Kristin V Tarbell
Journal:  J Autoimmun       Date:  2018-02-10       Impact factor: 7.094

Review 4.  Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling.

Authors:  Antonio Manzo; Michele Bombardieri; Frances Humby; Costantino Pitzalis
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

5.  TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.

Authors:  M Pyzik; C A Piccirillo
Journal:  J Leukoc Biol       Date:  2007-05-02       Impact factor: 4.962

6.  Depletion of CD4+ CD25+ regulatory T cells confers susceptibility to experimental autoimmune encephalomyelitis (EAE) in GM-CSF-deficient Csf2-/- mice.

Authors:  Debjani Ghosh; Alan D Curtis; Daniel S Wilkinson; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2016-06-02       Impact factor: 4.962

7.  Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy.

Authors:  Guillaume Churlaud; Fabien Pitoiset; Fadi Jebbawi; Roberta Lorenzon; Bertrand Bellier; Michelle Rosenzwajg; David Klatzmann
Journal:  Front Immunol       Date:  2015-04-15       Impact factor: 7.561

Review 8.  How does the immune system learn to distinguish between good and evil? The first definitive studies of T cell central tolerance and positive selection.

Authors:  Paweł Kisielow
Journal:  Immunogenetics       Date:  2019-08-15       Impact factor: 2.846

Review 9.  Getting to the Heart of the Matter: The Role of Regulatory T-Cells (Tregs) in Cardiovascular Disease (CVD) and Atherosclerosis.

Authors:  Caraugh J Albany; Silvia C Trevelin; Giulio Giganti; Giovanna Lombardi; Cristiano Scottà
Journal:  Front Immunol       Date:  2019-11-28       Impact factor: 7.561

Review 10.  Regulatory T Cells in Systemic Sclerosis.

Authors:  Camelia Frantz; Cedric Auffray; Jerome Avouac; Yannick Allanore
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

View more
  4 in total

1.  Low-Zone IL-2 Signaling: Fusion Proteins Containing Linked CD25 and IL-2 Domains Sustain Tolerogenic Vaccination in vivo and Promote Dominance of FOXP3+ Tregs in vitro.

Authors:  Kayla B DeOca; Cody D Moorman; Brandon L Garcia; Mark D Mannie
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

Review 2.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

Review 3.  New insights on the role of human leukocyte antigen complex in primary biliary cholangitis.

Authors:  Giacomo Mulinacci; Andrea Palermo; Alessio Gerussi; Rosanna Asselta; Merrill Eric Gershwin; Pietro Invernizzi
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

Review 4.  Molecular Mimicry and Uveitis.

Authors:  Gerhild Wildner; Maria Diedrichs-Möhring
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.